Venous thromboembolism in multiple myeloma is associated with increased mortality.

Martin W Schoen Kenneth R CarsonSuhong LuoBrian F GageAng LiAmber AfzalKristen M Sanfilippo

Published in: Research and practice in thrombosis and haemostasis (2020)

This study shows that VTE during the first 6-12 months of therapy is associated with increased mortality in patients with MM. Studies evaluating thromboprophylaxis in patients at high risk of thrombosis are needed.

Keyphrases

venous thromboembolism
direct oral anticoagulants
multiple myeloma
cardiovascular events
risk factors
cardiovascular disease
coronary artery disease
case control
mesenchymal stem cells